Table 1.
Monoclonal antibodies approved for clinical use and the SARS-CoV-2 variant evasion of neutralization.
| Lineage | Tixagevimab/Cilgavimab | Sotrovimab (no Longer Recommended, According to NIH Living Guidance) |
Casirivimab/ Imdevimab (no Longer Recommended, According to NIH Living Guidance) |
Bebtelovimab (no Longer Recommended, According to NIH Living Guidance) |
Bamlanivimab/ Etesevimab (no Longer Recommended, According to NIH Living Guidance) |
|---|---|---|---|---|---|
| Alpha | |||||
| Beta | |||||
| Gamma | |||||
| Delta | |||||
| Omicron | |||||
| BA.1 | |||||
| BA.1.1 | |||||
| BA.2 | |||||
| BA.2.12.1 | |||||
| BA.2.75.2 | |||||
| BA.4 | |||||
| BA.4.6 | |||||
| BA.5 | |||||
| BQ.1/BQ1.1 | |||||
| XBB (BA2.10.1 and BA.2.75 recombinant) |